康柏西普治疗视网膜静脉阻塞继发黄斑水肿

Intravitreal injection of conbercept for macular edema due to retinal vein occlusion

目的评价玻璃体内注射康柏西普治疗视网膜静脉阻塞继发黄斑水肿的疗效。方法回顾性分析2014年7月至2015年5月我院收治的视网膜静脉阻塞继发黄斑水肿32例（34眼）。其中视网膜中央静脉阻塞12例（14眼），视网膜分支静脉阻塞20例（20眼）。病程2周-18个月。均在玻璃体内注射康柏西普0．05ml（0．5mg），比较治疗前及治疗后2周至3个月各时间段的最佳矫正视力及OCT测量的黄斑中心区视网膜厚度。结果治疗前及治疗后2周、1个月、2个月及3个月最佳矫正视力（10gMAR）依次为0．71±0．06、0．45±0．33、0．55±0．16、0．51±0．29和0．57±0．41，治疗后视力明显提高，与治疗前相比均有统计学意义（P〈0．01）。治疗前及治疗后各时间段黄斑中心区视网膜厚度依次为（564±127）μm、（278±92）μm、（325±66）μm、（297±54）μm和（344±91）μm，治疗后黄斑水肿明显改善，与治疗前相比差异均有统计学意义（P〈0．01）。结论玻璃体内注射康柏西普可以有效减轻视网膜阻塞继发的黄斑水肿，提高视力。

Objective To evaluate the efficacy of conbercept intravitreal injection for macular edema caused by retinal vein occlusion （RVO）. Methods Thirty-four eyes of 32 patients with macular edema secondary to RVO from July 2014 to May 2015 in our hospital were retrospectively analyzed. The duration was from 2 weeks to 18 months. All patients received intravitreal injection of O. 05 ml（O. 5 rag） conbercept. The best corrected visual acuity（ log MAR） and the central macular thickness measured by OCT were observed before treatment and 2 weeks to 3 months after treatment. Results The best corrected visual acuity（logMAR） before treatment and 2 weeks, 1,2,3months after treatment were 0.71±0.06,0.45 ± 0.33,0.55 ±0.16,0.51 ± 0. 29,0.57 ± 0.41, successively. After treatmemt, the BCVA were higher than before treatmemt （ P 〈 0.01 ）. The central macular thickness before treatment and after treatment were （ 564 ± 127 ） μm, （ 278 ± 92 ）μm, （ 325 ±66 ） μm, （ 297± 54 ） μm, （ 344±91 ） μm, successively. After treatmemt the thieknes were lower than that before treatmemt（ P 〈 0.01 ）. Conclusion Intravitreal injection of eonbercept for macular edema caused by RVO can improve the visual acuity and relieve macular edema.